This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Doublebase Dayleve Gel

OTC
Read time: 2 mins
Last updated: 08 Jan 2020

Summary of product characteristics


1. Name of the medicinal product

Doublebase Dayleve Gel


2. Qualitative and quantitative composition

Isopropyl Myristate 15% w/w

Liquid Paraffin 15% w/w

For excipients see Section 6.1.


3. Pharmaceutical form

White opaque gel


4.1. Therapeutic indications

A long lasting highly emollient and protective hydrating base for regular first-line treatment and prophylaxis of dry or chapped skin conditions which may also be pruritic (itchy) or inflamed.

Doublebase Dayleve Gel may also be used as an adjunct to other topical treatments.


4.2. Posology and method of administration

For external use only.

For adults, the elderly, infants and children.

• Apply Doublebase Dayleve Gel to the affected areas morning and night, or as often as necessary.

• For best results use a few gentle strokes to smooth Doublebase Dayleve Gel across the skin in the same direction as hair growth. If necessary, allow time for any excess to soak in. Do not rub vigorously.

• Doublebase Dayleve Gel may also be applied before washing, showering or having a bath to prevent further drying of the skin.

If additional topical treatments are being used on the same skin areas, Doublebase Dayleve Gel should be applied between these applications.


4.3. Contraindications

Do not use in cases of known sensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

No special precautions.


4.7. Effects on ability to drive and use machines

No special precautions


4.8. Undesirable effects

Although Doublebase Dayleve Gel has been specially formulated for use on dry, problem or sensitive skin, local skin reactions can occur in rare cases. In this event, treatment should be discontinued.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9. Overdose

Not applicable.


5.1. Pharmacodynamic properties

ATC Code: D02AX

The oily ingredients, isopropyl myristate and liquid paraffin, encourage rehydration and softening of dry skin by forming an occlusive barrier within the skin surface, thus reducing drying from evaporation of water that diffuses from the underlying layers.


5.2. Pharmacokinetic properties

The product is formulated to provide long-lasting skin hydration. Because Doublebase Dayleve Gel is designed to deliver the emollient ingredients into the stratum corneum when gently applied to areas of dry skin, it is relatively non-greasy despite its high oil content.


5.3. Preclinical safety data

No relevant information additional to that contained elsewhere in this SPC.


6.1. List of excipients

Glycerol

Povidone

Carbomer

Sorbitan Laurate

Trolamine

Phenoxyethanol

Purified Water


6.2. Incompatibilities

None known.


6.3. Shelf life

36 months


6.4. Special precautions for storage

Do not store above 25°C.

Do not freeze.


6.5. Nature and contents of container

PVC bottle (500 g) with polypropylene metering pump.

Polyethylene laminate tube (25 g and 100 g) with polypropylene screw cap.


6.6. Special precautions for disposal and other handling

Not applicable.


7. Marketing authorisation holder

Diomed Developments Limited

T/A Dermal Laboratories

Tatmore Place

Gosmore

Hitchin

Hertfordshire, SG4 7QR

UK


8. Marketing authorisation number(s)

PL 00173/0199


9. Date of first authorisation/renewal of the authorisation

07/03/2007


10. Date of revision of the text

20/12/2019

4.1 Therapeutic indications

A long lasting highly emollient and protective hydrating base for regular first-line treatment and prophylaxis of dry or chapped skin conditions which may also be pruritic (itchy) or inflamed.

Doublebase Dayleve Gel may also be used as an adjunct to other topical treatments.

4.2 Posology and method of administration

For external use only.

For adults, the elderly, infants and children.

• Apply Doublebase Dayleve Gel to the affected areas morning and night, or as often as necessary.

• For best results use a few gentle strokes to smooth Doublebase Dayleve Gel across the skin in the same direction as hair growth. If necessary, allow time for any excess to soak in. Do not rub vigorously.

• Doublebase Dayleve Gel may also be applied before washing, showering or having a bath to prevent further drying of the skin.

If additional topical treatments are being used on the same skin areas, Doublebase Dayleve Gel should be applied between these applications.

4.3 Contraindications

Do not use in cases of known sensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

No special precautions.

4.7 Effects on ability to drive and use machines

No special precautions

4.8 Undesirable effects

Although Doublebase Dayleve Gel has been specially formulated for use on dry, problem or sensitive skin, local skin reactions can occur in rare cases. In this event, treatment should be discontinued.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).